Lexaria Bioscience Corp. announced a technical development using DehydraTECH to reduce side effects, while Eli Lilly and Novo Nordisk dominate the obesity drug market.
2 reports, 1 independent
Updated Aug 6
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Lexaria Bioscience Corp. announced a technical development using DehydraTECH to reduce side effects, while Eli Lilly and Novo Nordisk dominate the obesity drug market.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Lexaria's drug study is underway in Australia and shows superiority over a competitor to STEP's semaglutide.Sub-event
Lexaria develops technology to reduce GLP-1 side effects as Lilly and Novo Nordisk maintain market dominance.1 source
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Novo Nordisk strengthens its R&D pipeline in the fields of obesity and diabetes.
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
Coverage
Newest first; wire copies grouped- ACCESS NewswireGLP-1 "Arms Race" Broadens to Include Dozens of Companies Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / Lexaria Bioscience C
- ACCESS NewswireLexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry The fastest growing sector in the global pharmaceutical industry is struggling to face it